Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company closer to FDA submission. More: Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone Source: News
read moreInsmed has revealed results from a trial of Arikayce, which could pave the way for a significant label expansion for the Mycobacterium avium complex (MAC) treatment. More: Insmed sets up Arikayce for a significant label expansion on new ph. 3
read moreA pair of rivals developing drugs for common retinal diseases are not seeing eye to eye. EyePoint on Friday filed a lawsuit in Massachusetts Superior Court accusing Ocular Therapeutix of engaging in a “malicious campaign” against EyePoint. More: EyePoint lawsuit
read moreThe agency identified 14 cases of vitamin B6 deficiency-associated seizures in patients using the common Parkinson’s disease drug combo of levodopa and carbidopa. More: FDA mandates label updates to common Parkinson's meds based on seizure risk finding Source: fierce
read moreWatch out, Johnson & Johnson. Dizal has reported positive phase 3 results for its oral Zegfrovy that could put more pressure on the pharma giant’s injectable Rybrevant in non-small cell lung cancer. More: Dizal's Zegfrovy clinches landmark phase 3 win
read moreWith patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions in the country, with one company saying it will
read more© 1994 - 2026 B.M. Pharmaceuticals